Erschienen in:
13.04.2016 | Editorial
Vonoprazan: MarKed Competition for PPIs?
verfasst von:
David R. Scott, Elizabeth A. Marcus, George Sachs
Erschienen in:
Digestive Diseases and Sciences
|
Ausgabe 7/2016
Einloggen, um Zugang zu erhalten
Excerpt
Contemporary therapies for the treatment of acid-related diseases such as gastroesophageal reflux disease (GERD) and peptic ulcer disease (PUD), as well as
Helicobacter pylori infection, rely on acid suppression for symptom relief, healing, and eradication, respectively. Inhibition of the gastric H
+,K
+-ATPase, the final step in the acid secretion pathway, by proton pump inhibitors has been the treatment of choice since the approval of omeprazole for clinical use 30 years ago [
1]. PPIs were a vast improvement over the H
2 receptor antagonists (H
2RAs) and antacids for symptom relief and for healing of GERD and PUD. …